

Please welcome Dana Acklin, BA the new MOST Project Manager at the StrokeNet NCC!

Please include Dana on all MOST correspondence going forward (acklindr@ucmail.uc.edu).

Congratulations to the first sites to complete their fully executed Clinical Trials Agreement!

As of 12/7/2018:

- UCSD La Jolla and UCSD Hillcrest Hospital, San Diego, CA: PI - Brett Meyer, MD
- Henry Ford Hospital, Detroit, MI; PI - Daniel Miller, MD
- University of Wisconsin Health University Hospital, Madison, WI; PI - Azam S. Ahmed, MD
- Medical University of South Carolina; PI - Chirantan Banerjee, MD
- Regions Hospital, St. Paul, MN; PI - Haitham Hussein, MD
- SUNY Upstate University Hospital, Syracuse, NY; PI - Julius Gene Latorre, MD
- Memorial Hermann-Texas Med Center, Houston, TX; PI - Andrew Barreto, MD, MS
- University of Utah Health, Salt Lake City, UT; PI - Adam DeHavenon, MD
- Wellspan Health – Wellspan York Hospital, York, PA; PI - Brent Becker, MD

FAQS

What expiration date should be used for the FDA FDQ Form 3455, and NIH StrokeNet Financial Conflict of Interest Form (fCOI) when uploading to WebDCU?

Please enter an expiration date of **4/24/2019** for both forms. This is the date that the continuing review is due with the CIRB at which time all study team members will fill out new forms.

Do pharmacists need to be on the FDA Form 1572?

No. Since pharmacists are not reconstituting study medication, and simply dispensing the assigned study drug kit they do not need to be on the 1572. Pharmacists who require access to WebDCU and who will maintain receipt of study drug shipments should be added to the Delegation of Authority Log.

Other non-essential study personnel who require access to WebDCU, e.g. administrative roles or regulatory coordinators, also do not need to be added to the 1572 but should be listed on the Delegation of Authority Log.

Ancillary Studies Solicitation

Please contact Dr. Adeoye (adeoyeo@uc.edu) and Iris Deeds (deedsss@uc.edu) with MOST ancillary study proposals. Please note that ancillary studies should have separate hypothesis with separate funding from MOST. Subgroup analysis ideas will be solicited at a later time.

MOST Protocol Q&A

Thank you to everyone who joined the MOST Protocol Q&A! To access the presentation slide show, go to <https://www.nihstrokenet.org/education>, and to access the FAQ list generated from the call, go to <https://www.nihstrokenet.org/clinical-trials/most/resources>.